IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of ...
The Company will issue a release after the oral presentation that will include the 5-year OS data, which is the longest OS follow-up in a randomized trial in metastatic uveal melanoma patients. Beyond ...
Explore the hidden economic burdens of eye cancer in India and the urgent need for awareness, access, and specialized care.
Syncona’s maturing portfolio entering a period of significant clinical and strategic milestones, positioning the business for near-term value creation and enabling returns to shareholdersHigh-calibre ...
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: ...
Syncona's maturing portfolio entering a period of significant clinical and strategic milestones, positioning the business for near-term value creation and enabling returns to shareholdersHigh-calibre ...
Detailed price information for Bioinvent International Ab (BOVNF) from The Globe and Mail including charting and trades.
“When we talk about recurrence of melanoma, we actually worry more about what we cannot see, what's on the inside,” Dr. Justine V. Cohen of the Dana-Farber Cancer Institute told CURE®. Patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results